Predicting Myocardial Fibrosis and Ventricular Arrhythmia Risks in Adults with Mitral Valve Prolapse The SCIMITAR Study

What this Trial Is About

This research aims to develop a scoring model to predict myocardial fibrosis detected by cardiac magnetic resonance CMR in patients with mitral valve prolapse MVP. It also seeks to identify features that may increase the risk of mild ventricular arrhythmias or sudden cardiac death in these patients. MVP patients typically have a good outlook, but a small group may experience dangerous heart rhythm problems, which this study investigates. The study includes two groups patients enrolled prospectively who will undergo a full clinical assessment including echocardiography, resting ECG, 24-hour ECG monitoring, and CMR within six months of each other and patients enrolled retrospectively who have already completed these examinations between 2016 and 2023. This observational study collects detailed clinical and imaging data to explore links between heart structure, function, and rhythm abnormalities. Participants will be evaluated using various tests such as transthoracic echocardiography, ECG monitoring, and CMR to measure heart structure and scarring. Researchers will analyze these data to predict fibrosis and risk of arrhythmias or sudden cardiac death. The study will monitor outcomes through June 2026, focusing on clinical, echocardiographic, ECG, and CMR parameters to improve understanding of risk factors in MVP patients.

Multiparametric SCores for Prediction of Myocardial fIbrosis in Patients With MITral vAlve pRolapse